Can we prevent or treat renal dysfunction in acute heart failure?

Heart Fail Rev. 2012 Mar;17(2):291-303. doi: 10.1007/s10741-011-9253-3.

Abstract

Most patients with heart failure (HF) already have or develop renal dysfunction; this might contribute to their poor outcome. Current treatment for HF can also contribute to worsen renal function. High furosemide doses are traditionally associated with worsening renal function (WRF), but patients with fluid overload may benefit of aggressive fluid removal. Unfortunately, promising therapies like vasopressin antagonists and adenosine antagonists have not been demonstrated to improve outcomes. Likewise, correction of low renal blood flow through dopamine, inotropic agents, or vasodilators does not seem to be associated with a clear benefit. However, transient WRF associated with acute HF treatment may not necessarily portend a poor prognosis. In this review, we focus on the strategies to detect renal dysfunction in acute HF, the underlying pathophysiological mechanisms, and the potential treatments.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Adenosine / antagonists & inhibitors
  • Biomarkers / metabolism
  • Cardiotonic Agents / therapeutic use
  • Diuretics / therapeutic use
  • Dopamine / therapeutic use
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Kidney / physiopathology*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / etiology*
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Prognosis
  • Vasodilator Agents / therapeutic use*
  • Vasopressins / antagonists & inhibitors

Substances

  • Biomarkers
  • Cardiotonic Agents
  • Diuretics
  • Mineralocorticoid Receptor Antagonists
  • Vasodilator Agents
  • Vasopressins
  • Adenosine
  • Dopamine